Direct-to-Patient DtP Drug Supply
Enabling Direct-To-Patient (DtP) Drug Supply
Interactive Response Technology
Clinical trials are becoming more patient-centric, with increasing use of virtual and hybrid trials, electronic patient-reported outcome (ePRO) data collection through patients own devices, resulting in more requests for studies with direct-to-patient drug shipping for patients who aren’t able to leave home to attend clinical sites, or just to reach more, and increasingly diverse patient population who cannot or will not travel.
In today’s COVID environment, with some patients unable to access hospitals and clinics, or even reluctant to use public transport, patients centricity means being able to supply Investigational Medicinal Products (IMPs) directly to a patient's home, with trial medication despatched from the clinical site, from a dedicated depot or,. in some countries, from Pharmacies ( e.g., Denmark).
S-Clinica's Direct-to-Patient module is specifically designed to manage this process, driven by the S-Clinica Anticipatory Management Engine and performing the following tasks;
Account for Unblinding Scenarios
Maintain Patient Privacy
Handle Temperature Deviations
Handle Labelling requirements for just in time delivery
Flexible enough to account for individual patient challenges
Perform drug accountability and drug destruction
Flexible supply modelling